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COMMENTARY

Conducting a supportive oncology clinical
trial during the COVID‑19 pandemic: challenges
and strategies
Jie Deng1* , John N. Lukens1, Joy C. Cohn1, Erin McMenamin1, Barbara Murphy2, Bryan A. Spinelli3,
Niya Murphy1, Alicia K. Steinmetz1, Megan A. Landriau1 and Alexander Lin1

Abstract
The coronavirus disease 2019 (COVID-19) pandemic resulted in severe interruptions to clinical research worldwide.
This global public health crisis required investigators and researchers to rapidly develop and implement new strategies and solutions to mitigate its negative impact on the progress of clinical trials. In this paper, we describe the challenges, strategies, and lessons learned regarding the continuation of a supportive oncology clinical trial during the
pandemic. We hope to provide insight into the implementation of clinical trials during a public health emergency to
be better prepared for future instances.
Trial registration: ClinicalTrials.gov, a service of the US National Institute of Health (NCT 03030859). Registered on 22
January 2017.
Keywords: Clinical trials, COVID-19, Pandemic, Trial operation, Telehealth, Virtual visits, Participant safety,
Lymphedema, Fibrosis, Head and neck cancer
Background
The coronavirus disease 2019 (COVID-19) is an unprecedented global public health crisis with significant impacts
at both macro and micro levels [1]. The pandemic has led
to a devastating loss of human lives, presented challenges
to the economy and educational and social structures,
and profoundly influenced the fields of healthcare, medicine, and research. For months, operations around the
world were either put on hold or moved entirely online
causing an everlasting shift in work-life balance.
The COVID-19 pandemic and the preventative measures adopted by the USA to curb the spread of the virus
resulted in restrictions, interruptions, and challenges
to clinical research. Clinical trials are of paramount
*Correspondence: jiedeng@nursing.upenn.edu
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importance for the advancement and development of
novel treatment interventions [2]. On March 18, 2020, the
US Food and Drug Administration (FDA) issued a guidance for industry, investigators and institutional review
boards conducting clinical trials during the COVID-19
pandemic [3]. However, several reports have indicated
the significant impact of COVID-19 on the conduction
of clinical trials. A study analyzing the clinical trials’
data from ClinicalTrials.gov between January 2018 and
December 2020 found that the number of newly started
clinicals, reported results, and new drug applications had
a marked drop in quarters 2 and 3 of 2020, compared
with the same period in 2019. This indicated the magnitude of the impact of the first wave of COVID-19 on clinical trial development and implementation [4]. A recent
systematic review identified major challenges related to
clinical trial operations, such as limited access to clinics
for essential study visits, difficulty in recruiting patients
who are reluctant to visit clinics, potential exposures to
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the risk of acquiring the infection, delayed study assessment, and high drop-out rate, all of which will affect data
integrity [2].
In this report, we intend to share our experiences of
conducting one supportive oncology clinical trial during the COVID-19 pandemic [3, 5]. We will describe the
challenges, strategies, and lessons learned regarding the
continuation of a participant-centered clinical trial during a global pandemic. This includes decisions made to
ensure the safety of both participants and trial staff, as
well as decisions directed at overcoming pandemicrelated challenges in an effort to continue with essential
data collection and other important trial activities. We
hope our experiences can contribute to understanding
the impact the COVID-19 pandemic has had on the conduct of clinical trials and provide insight into implementing clinical trials during a global health crisis.

Methods
Trial introduction

The purpose of our study was to develop and test a program for head and neck cancer survivors to promote
self-care activities for managing lymphedema and fibrosis after completion of therapist-directed therapy [5, 6].
We developed and finalized the study intervention during
Stage I of the project (pre-COVID). During Stage II of the
study, we conducted a pilot randomized clinical trial to
test the study intervention. In our previous publication,
we presented the study work flow (please see the Study
Protocol Items: Recommendation for Interventional Trials (SPIRIT) Figure (Fig. 1)) [6]. Namely, after the completion of the baseline visit, participants were randomly
assigned to one of three groups: usual care, usual care
plus the self-care training, or usual care plus self-care
training with additional boost training sessions. We then
followed the participants for 12 months to evaluate outcomes such as lymphedema and/or fibrosis progression,
symptom burden, functional status, self-efficacy and
adherence to the program, and overall satisfaction of the
study intervention [5, 6].
Trial operation during the COVID‑19 pandemic

During the onset of the COVID-19 crisis, we were in the
process of recruiting participants and conducting followup assessment visits for stage II of the study. To ensure
the safety of participants and study staff during the pandemic, we modified the study protocol accordingly and
moved all project-related activities from in-person to
online. In the Results section, we summarized the unique
issues and challenges we encountered in recruiting participants and conducting study visits virtually during the
pandemic. We presented the strategies we used to maintain research conduct compliance.
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Results
Transition to online

On March 13, 2020, the Clinical Research Guidance
issued by the University of Pennsylvania Health System
(Penn Medicine) and Penn Institutional Review Board
(IRB) ordered that clinical research in the Penn Medicine
Health System was limited to essential clinical trials only
[7]. Essential clinical trials were those that enrolled or followed patients with life-threatening or serious conditions
for which participation in the clinical trial holds the clear
prospect of direct patient benefit. Subsequently, the City
of Philadelphia issued a Stay-at-Home Order detailing
business activity restrictions resulting from the COVID19 pandemic [8]. Our ongoing supportive clinical trial
was suspended, and our entire research team transitioned
to work from home. This required a pause in recruitment
and data collection for two months (March 2020 to May
2020) as well as an indefinite hold on all in-person project-related activities. During this time, the protocol was
amended to allow our team to transition project-related
activities to be performed virtually. Prior to executing
this major shift, we received approval from the Penn
IRB, Abramson Cancer Center, School of Nursing, and
the Funding Agency, American Cancer Society. Virtual
study visits resulted in unique issues and challenges for
trial recruitment and data collection which required the
rapid development and implementation of new strategies
and solutions. We were able to re-open recruitment and
conduct data collection virtually to minimize the negative impact of the pandemic on patient health.
Issues and challenges
Recruitment issues unique to COVID‑19

During March 2020 (the first month of our statewide
lockdown), 12 patients who previously expressed their
interest declined to participate in the study. Many
patients declined for reasons related to COVID-19
including not meeting eligibility criteria, change of mind
(loss of interest), time constraints (particularly relating
to additional constraints due to the pandemic, such as
childcare), challenges committing to a yearlong study in
a time of uncertainty, and distance from the location and
concerns about travel once the study could be conducted
in-person.
To be eligible for participation in our study, patients
were required to have completed initial lymphedema
therapy with their therapist. However, many interested
patients were unable to complete the initial therapistdirected lymphedema treatment during the pandemic
due to several factors, such as statewide travel restrictions and shutdown of clinics and offices. These patients
ultimately chose not to pursue lymphedema therapy altogether and thus, were ineligible for study participation.
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Fig. 1 Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) Figure

Of the patients who declined due to change of mind
(loss of interest), some of these patients stated that their
lymphedema/fibrosis was not much of a concern for
them, and some patients declined because they wanted to
continue with their own self-care routine during the pandemic. In addition, some patients felt time constraints
due to the demands created by the pandemic precluded
participation. For example, one patient declined due
to lack of childcare and the demands of homeschooling
three children. Another patient was moving out of state
to care for a relative who was ill and could not commit
the time. Some patients were unable to commit to the
study activities due to loss of employment or overwhelming work obligations resulting from the COVID-19 crisis.

Lastly, a few patients were not willing to commit to an
online study that had the potential to convert to in-person (and thus requiring travel should COVID-19 restrictions be lifted).
Data collection and other challenges

We transitioned study visits online using a telehealth system that was compliant to the Health Insurance Portability and Accountability Act (HIPAA) and approved by the
Penn IRB to ensure participants’ safety and to continue
with essential data collection and other important trial
activities. While telehealth was critical for study continuation, we experienced some unique issues and challenges
in collecting research data. First, the response rate for
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scheduling follow-up data collection visits was low at the
beginning of the pandemic, for example, 69% (9/13) in
April 2020. The response rate gradually increased starting
June 2020 (e.g., greater than 90%). Second, if a patient did
not have internet access and/or access to a video-capable device, the virtual study session could not be completed. Fortunately, all participants (N=61) had internet
access. Over 95% of the participants (58 out of 61) had a
video-capable device, but nearly 5% (3 out of 61) of the
participants were without an adequate device for virtual
study visits. Occasionally, patients with internet access
experienced slow connection speeds and lag times during
the virtual study visit. One patient was not comfortable
downloading the HIPAA compliant telehealth app onto
his device and preferred to use other software, which was
not approved by the Penn IRB. Lastly, some pertinent but
critical data (e.g., assessment of neck range of motion,
hands-on physical exam grading) had to be excluded
because these data had to be collected in person.
COVID-19 posed an additional challenge concerning the licensure of physical therapists (PT), certified in
lymphedema management, who provided the intervention. Prior to COVID-19, participants living outside
Pennsylvania could come to the study site in Philadelphia
for in-person intervention sessions. When we switched
to telehealth visits, licensure became an issue for those
patients who resided in a state other than the state where
the PT was licensed. Due to these licensure requirements
for telehealth, we were unable to recruit several eligible
patients who were interested in the study but lived in
states where our therapists were not licensed to practice. When possible, a temporary license to practice was
obtained if allowed under the state of emergency declaration in the patient’s state of residence.
Strategies used during the pandemic
Strategies used to recruit new patients

To articulate the strategies used to recruit patients virtually during the pandemic, it is important to review
what approaches we used to successfully recruit participants before the COVID-19 pandemic. The recruitment methods pre-COVID are summarized as follows:
(1) we screened for eligible participants in oncology
clinics (radiation oncology and ENT) in collaboration
with both physicians and nurse practitioners, according to our inclusion/exclusion criteria; (2) we distributed study flyers to physicians, nurse practitioners, and
nurse navigators to share with patients; (3) we followed
up on any potential patients referred to us from physicians, therapists, or participants on our study; and (4)
we contacted potentially eligible patients via phone call
or email. For patients that were interested in the study,
we sent them the informed consent and set up a time to
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meet with them in person at their upcoming oncologic
appointments. For participants that were undecided, we
followed up with them via phone call or email. In addition, our study staff established a relationship with the
clinic team members to help coordinate recruitment and
data collection for patients on study. Study staff attended
patient visits in the oncology clinics and interacted
directly with patients and clinicians (e.g., physician, nurse
practitioner). Before the pandemic, recruitment and data
collection were conducted in person and required the
cooperation of all key stakeholders: patients, study staff,
and clinicians.
Recruitment strategies during the COVID‑19 pandemic After the study was suspended for two months,
we re-opened for virtual recruitment with approval from
the Penn IRB, Abramson Cancer Center, and funding
agency (American Cancer Society). The following strategies and resources utilized during the COVID-19 pandemic enabled the study to continue and even helped
boost recruitment. (1) We updated the protocol and
trained team members on the use of telehealth to recruit
and enroll participants. (2) We communicated with the
clinic team to inform them that we re-opened the study.
We then proceeded to conduct all study activities virtually through a HIPAA-compliant telehealth system, which
was the same platform used in our cancer center. (3) We
continued to employ some of the pre-COVID recruitment strategies if they were applicable during the pandemic. For instance, we screened for eligible participants
who had an upcoming virtual appointment with their
providers. We followed up on potential patients referred
to us from physicians, therapists, or participants on our
study via phone call and/or email. (4) We collaborated
with the local head and neck cancer support group and
distributed electronic versions of the study flyers to the
group members. (5) We also communicated with local
lymphedema clinics and provided study flyers (electronic
version) to them to help with participant recruitment.
Despite the unique challenges associated with COVID19 restrictions, our study team improved the recruitment rate from 2-3 participants per month pre-COVID
to 3–4 participants per month during the pandemic,
which was attributed to the strategies mentioned above.
Once we identified the potential patients for recruitment,
we worked to establish trust, effectively communicate
the potential benefits of participation, and actively listen for ways to reduce participant burden. The potential benefits of their participation were communicated
in laypersons’ terms and included the potential impact
of their participation on them, the community, and science. We reduced participant burden by streamlining
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the consenting process. Potential patients were screened
over the phone first. If they were interested, we sent the
informed consent document for their full review prior to
virtually meeting them. We did not push patients to commit to the study if they were unsure. Instead, we asked to
stay in touch and followed up with them regularly with
their permission.

Strategies used for retention

The ability to stay connected with our patients during
this pandemic redefined our communication strategies,
which enabled our team to create more personalized
interactions with our patients. Throughout the COVID19 pandemic, our team found it essential to prioritize the
well-being of each patient, which made them feel valued
and respected. For follow-up patients, we began each
conversation by asking how they were doing, genuinely
expressing interest in their well-being, and discussing any
concerns or questions they had. We realized that even
though our team was working remotely, some patients
did not have that option and had to continue working in
their respective offices. Taking this into consideration we
decided to be more flexible with scheduling study visits
and extended the window of time allotted for each follow-up visit. This particularly helped patients who could
not make time to see us previously.
Our staff reviewed the study databases regularly and
determined which participants needed to be scheduled
for upcoming appointments based on their study visit
windows. Once that determination was made, one of our
team members emailed participants to schedule a virtual,
telehealth visit. In that same email, step-by-step instructions for downloading the official telehealth platform,
and other study visit-related instructions were attached.
Participants were scheduled based on their availability. If
the participant was unresponsive by email, we contacted
them by phone a few days later, using a HIPPA compliant mobile application called Enterprise (Vonage), and
proceeded with scheduling. The method used to contact
participants was rotated each month between phone
calls and emails. Patients often express concern about
answering calls from unknown telephone numbers. Calls
made by study staff using the Enterprise application are
identified as originating from the institution, thus eliminating the concern about unwanted solicitations. The
team member attempts to contact the patient no more
than three times total. Once a date is determined, the
team member scheduled the event on the HIPAA compliant telehealth platform and on the Outlook calendar.
It is important to note that retaining patients can prove
to be difficult with longitudinal studies. However, with
the combined efforts of our diligent team along with our
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understanding patients and supportive clinic team, we
were able to successfully carry out our follow-up data
collection visits virtually and maintain adequate progress
of the project.
Strategies used to conduct virtual study visits

The Research Assistant (RA) leading the visit and the
Research Coordinator opened the HIPAA compliant
telehealth platform application and joined the meeting
at least 15 min prior to the scheduled start time for virtual study visits. This allowed for any technical issues to
be fixed prior to the participant joining the virtual visit.
For initial visits, the Principal Investigator joined the
call for quality assurance purposes. Once the participant joined the meeting, the Research Coordinator and
PI muted their audio and video capabilities. At this point,
the participant only saw the RA. The RA asked the participant about their current self-care regimen and any
new symptoms they may be experiencing related to their
lymphedema or fibrosis. The RA completed the study
surveys with the participant. Then, the RA collected
lymphedema and fibrosis treatment and self-care information; during this time, the RA allowed the patient to
speak openly about their self-care routine. During the
virtual physical examination of the head and neck region,
the RA ensures that the patient is in a well-lit room and
asks the patient to indicate where they feel swelling/tightness. The RA then asks the patient to bring their device
close to their face and neck in order to conduct a more
detailed visual examination. The virtual study visit takes
less than 30 min.
When conducting virtual visits over a telehealth platform, it is important to give participants ample time to
finish speaking. Often, a lag or delay in either the video or
audio may occur during a virtual session, so it can be easy
to interject or talk over someone. After completing multiple sessions, our staff learned how long to “pause” to let
our participant finish speaking.

Discussion
The impact of the COVID-19 pandemic on healthcare
system (including clinical research) is profound. Findings
from a recent systematic report that analyzed all active
RCTs from January 1, 2015, to December 31, 2020, indicated that the number of active trials increased annually from 2015 to 2019 but decreased in 2020 [9]. There
was a sharp decline in trial initiations in the months of
March, April, May, and June 2020. The largest decrease
was in April 2020, which later gradually recovered in
November 2020 [9]. Also, there was a statistically significant increase in the number of trials stopped during the
pandemic [9]. Similarly, our clinical trial had been suspended for almost three months due to the onset of the
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COVID-19 pandemic and then re-opened to recruit participants and conduct other data collection activities virtually. Although this was a challenging time, our research
team had learned how to use alternative strategies to
continuously conduct our trial.
Lessons learned

During the pandemic, ensuring the safety of trial participants was paramount. By conducting telehealth visits we
know that our research team minimized patients’ risk.
Telehealth allows for greater access to care in a more convenient and low-cost setting. Participants indicated that
telehealth allowed them to schedule an appointment at
their convenience and join the virtual meeting from the
comfort of their own home. Participants also reported
saving time and travel expense, issues that were particularly important to participants living outside of Philadelphia. Travel time and distance are common reasons why
potential participants declined to participate in the study
before the pandemic [10]. The advantage of using telehealth is that it allows patients to easily access resources
from wherever they are located, thus leading to more
patient involvement. At the end of our telehealth sessions, we ask patients about their overall experience and
satisfaction with telehealth. So far, all patients that have
completed the survey indicated that they would attend
another telehealth visit.

Conclusion
Based on the experience from the participants in our
study we concluded: (1) virtual study visits allowed for
continued communication and connection with our participants; (2) virtual study visits helped us to maintain
subject recruitment and facilitated retention during the
pandemic; (3) attending virtual study visits proved to be
acceptable and feasible by most of our participants; (4)
virtual study visits did not adversely impact collection
of self-reported outcome measures, such as surveys and
questionnaires; and (5) the preliminary data demonstrated the feasibility, acceptability, and potential efficacy
of providing a virtual self-care program for lymphedema
and fibrosis among the head and neck cancer survivor
population (data not presented). Conversely, we found
the following limitations related to virtual study visits: (1)
virtual study visits required patients have access to both
internet and video-capable devices; (2) virtual study visits
limited our capacity to collect physical examination data
and some objective in-person measures; and (3) physical
therapists could only see patients that lived in the states
in which they are licensed. These limitations indicated
a need to identify alternatives to an in-person physical
examination and/or training sessions. Some patients suggested a hybrid model which included both virtual study
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visits and a limited number of in-person interactions
with our study team and/or therapist. A hybrid model
would minimize in-person contact while allowing critical
research and clinical activities to continue.
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